Kornimate/medical-research-clean huggingface dataset:
aspirin and statins for prevention of atherosclerosis and arterial thromboembolism in systemic lupus erythematosus

Conditions: Atherosclerosis; Thromboembolism; Systemic Lupus Erythematosus

Summary: the purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (sle).

to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus. subclinical atherosclerosis is assessed by ultrasound study of the carotid vessels and ct scan of the coronary arteries for calcium scores. blood markers of endothelial activation will also be studied.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years 2. fulfillment of at least 4 of the american college of rheumatology (acr) criteria for sle 3. presence of any two of the following risk factors: * sle duration of \>= 5 years * postmenopausal * age \>= 40 years * diabetes mellitus * hypertension (140/90 mmhg) * serum low density lipoprotein (ldl) level \>= 2.6 mmol/l or total cholesterol \>= 5.5 mmol/l * obesity (body mass index \>= 27 kg/m2) * chronic current smoker * positive antiphospholipid antibodies * renal function impairment * persistent proteinuria \>= 1 gm/day for \>= 6 months 4. informed consent obtained exclusion criteria: 1. patients with known allergy to aspirin, or any other non-steroidal anti-inflammatory drugs (nsaids), or statins 2. patient with a history of severe gastrointestinal intolerance to aspirin (e.g., gastrointestinal bleeding) or other nsaids 3. patients with history of arterial or venous thromboembolism 4. patients receiving aspirin or other anti-platelet agents 5. patients receiving long-term non-aspirin nsaids 6. patients receiving anticoagulation therapy (e.g., warfarin) 7. patients with history of intolerance or allergy to the statins 8. pregnant or lactating women

Keywords: lupus atherosclerosis thrombosis statin lipid
medical expulsive therapy of single distal ureteral stones

Conditions: Ureteral Calculi

Summary: current therapeutic options for ureteral stones include active intervention as well as conservative "watch and wait" approaches. endoscopic treatment of ureteral stones has a high success rate and reliably results in immediate stone removal however, surgical as well as anaesthetic risks are not negligible and serious complications are possible. for many patients, a conservative treatment is an appealing option. watchful waiting, however, not always results in stone clearance and may be associated with recurrent renal colics. the therapeutic potential of alpha-blockers for ureteral stone disease has been investigated prompted by the detection of alpha-receptors in ureteral smooth muscle cells. blocking of such receptors, which are predominantly located in the distal part of the ureter results in relaxation of the ureteral wall and modulation of peristaltic activity. this mechanism has been proposed to facilitate stone passage for ureteral calculi. numerous clinical trials have revealed a significant improvement of the stone expulsion rate using the alpha-blocker tamsulosin. most of these studies were randomised but none were performed in a double-blind and placebo-controlled fashion. therefore, the objective of this trial was to evaluate the efficacy of medical expulsive therapy with tamsulosin in a randomised, double-blind, placebo-controlled setting.


Eligibility criteria:
inclusion criteria: * patients with a single 2 to 7mm ureteral stone below the common iliac vessels exclusion criteria: * presence of multiple ureteral stones * renal insufficiency (glomerular filtration rate below 60 ml/min) * urinary tract infection * a solitary kidney * pregnancy * history of ureteral surgery or previous endoscopic procedure * hypersensitivity to tamsulosin * current alpha-blocker, calcium-antagonist or corticosteroid medication

Keywords: adrenergic alpha antagonists drug therapy tamsulosin ureter
assessing tumor response and imrt treat plan after ic based on fdg-pet/ct for locally advanced hnscc

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: to evaluate the safety and efficacy of cisplatin plus intensity-modulated radiotherapy (imrt) based on fdg-pet/ct after induction chemotherapy (ic) for locally advanced head and neck squamous cell carcinoma.

current guidelines define that pre-ic target volumes must be used for radiotherapy (rt) planning. this prospective, phase ii trial assessed the results of patients with locally advanced squamous cell carcinoma of head and neck treatment with ic following by chemoradiotherapy (crt), using post-ic pet/ct images for imrt planning.

Eligibility criteria:
inclusion criteria: * male or female patients aged 18 years or over; * histologically confirmed locally advanced (stage iii and iv) head and neck squamous cell carcinoma (hnscc); * eastern cooperative oncology group (ecog) performance status 0 or 1; * signed written informed consent approved by the lithuanian bioethics committee (lbec); exclusion criteria: * positive serum pregnancy test in women of childbearing potential or breastfeeding; * presence of distant metastasis; * second primary tumor; * history of other malignancy within the last 5 years; * recurrent head and neck cancer; * serious uncontrolled concomitant disease that would contraindicate the use of any drugs use in this study as chemotherapy or radiotherapy; ; * inadequate organ function, evidenced by the following laboratory results: 1. absolute neutrophil count \<1,500 cells/mm3; 2. platelet count \<100,000 cells/mm3; 3. hemoglobin \<9 g/dl; 4. total bilirubin greater than the upper limit of normal (uln); 5. ast (sgot) or alt (sgpt) \>1,5 x uln; 6. alkaline phosphatase levels \>2,5 x the uln; 7. serum creatinine \>2,0 mg/dl or 177 umol/l.

Keywords: head and neck cancer pet/ct induction chemotherapy imrt
early detection and paramedical care of sexual difficulties in nervous system diseases: example of multiple sclerosis and brain tumors (neurosex)

Conditions: Low Grade Glioma of Brain; Multiple Sclerosis; Sexual Dysfunctions

Summary: this study aim to ensure that the implementation of a paramedical screening program and counseling in sexual health of patients with neurological pathologies (low-grade gliomas and multiple sclerosis) improves their sexual health.


Eligibility criteria:
inclusion criteria: 1. any major patient, followed in the ghpscf (groupe hospitalier pitié-salpêtrière charles foix) neurology department 2 for a diagnosis of low grade glioma or anaplastic glioma with loss 1p / 19q sub-reserve histo-molecular confirmation after national reading (pola) and presenting: * an msisq15 (multiple sclerosis intimacy and sexuality questionnaire) questionnaire with at least one of the items rated "4" or "5" and * a had (hospital anxiety and depression) questionnaire (depression component) with a score ≤ 11 2. any major patient with ms(multiple sclerosis), followed in the ghpscf department of neurology: * with an edss (expanded disability status scale) greater than or equal to 1 and * an msisq15 questionnaire with at least one of the items rated "4" or "5". * a had questionnaire (depression component) with a score ≤ 11 3. signature of informed consent 4. patient affiliated to a social security system exclusion criteria: 1. minor patients 2. pregnant women 3. patients who do not understand and / or speak french and / or are unable to sign consent 4. patients with neurological impairment 5. patients with chronic sexual disorders who have already received treatment. 6. patients with a had score (depression component) greater than 11 7. patients with ms who had a corticosteroid-treated outbreak in the last two months. 8. patients with low-grade glioma with clinical and / or radiological scalability during the last three months 9. any patient whose alteration of the general state would not allow to follow the program. 10. patients under legal protection for patient's partners: inclusion criteria: 1. any patient partner, whose patient has wished to participate and who has accepted. 2. signing of informed consent non-inclusion criteria: 1. minor partners 2. pregnant women 3. any person who does not understand and / or speak french and / or is unable to sign the consent 4. partners under legal protection
procalcitonin reduce antibiotic treatments in acute-ill patients (prorata)

Conditions: Bacterial Infections

Summary: the study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a pct-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.

clinical and laboratory signs are neither specific nor sensitive for diagnosis of sepsis in critically-ill patients. because delaying antimicrobial therapy may be deleterious, broad-spectrum antibiotics are widely used in icu -patients, even when they are not needed. in addition, only few well-designed studies concerning the duration of antibiotic treatment have been so far published. consequently, many patients received antibiotics during the icu stay. many studies have shown that exposure to antibiotics, the so called "selection pressure" is an independent risk factor for acquisition of resistance in individual patients. therefore, reducing antibiotic use is probably necessary to control antibiotic resistance. many clinical studies have shown that procalcitonin (pct) is able to distinguish the inflammatory response to infection from other types of inflammation and to distinguish bacterial from viral infections. recent studies have shown that pct guidance substantially and safely reduced antibiotic overuse in patients with lower respiratory tract infections. we aimed to evaluate the role of pct in reducing the use of antibiotics in icu adult patients. the study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a pct-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.

Eligibility criteria:
inclusion criteria: * patient hospitalised in the icu * bacterial infection suspected * at icu admission the patient do not receive antibiotics or receive antibiotics for less than 24hours and an interval between admission and inclusion \< 12 hours * during icu stay, provided that the interval between the start of suspected infection and inclusion is \< 12hours * written inform consent from the patient or relatives. the consent may be obtained after the enrollment if the patient is not able to give consent and if there is no relatives exclusion criteria: * age \< 18 years * pregnancy * patient expected to remain hospitalised in the icu for less than 3 days * neutropenia * infection or presumed infection requiring prolonged antibiotic therapy (endocarditis,osteo-articular infection, mediastinitis, deep abscess, tuberculosis, pneumocystis pneumonia, toxoplasmosis). * simplified acute physiology score ii at icu admission (calculated during the first 12h) * attending physician declining to use full life support.

Keywords: bacterial infections procalcitonin intensive care unit antibiotic therapy suspicion of bacterial infection or proven
electrical impedance tomography (eit) and physiotherapy

Conditions: Respiratory Disease

Summary: to compare the effect of different airway clearance techniques on lung ventilation by electrical impedance tomography.


Eligibility criteria:
inclusion criteria: * \>18 years old * surgery under anesthesia (pep and incentive spirometry) or healthy subjects * intervention time before first bed lift * cooperative * can perform devices techniques correctly exclusion criteria: * patients with pacemaker, implantable pumps or automatic implantable cardioverter defibrillator * patients with pulmonary disease (acute or chronic) * patients with cognitive problems * presence of patches or wounds in eit belt zone placement * patients with initial pain \> 2/10 * patients with severe obesity (bmi \> 35)
effect of caffeine on ocular circulation in high myopes

Conditions: High Myopia; Choroid

Summary: to investigate the effect of caffeine on ocular circulation by using optical coherence tomography and optical coherence tomography angiography. this study will evaluate blood supply to the inner and outer retina after consumption of 200mg caffeine capsule, in particular its effect in high myopes.

caffeine could cause vasoconstriction. previous studies revealed a reduction of retinal blood vessels diameter, a decrease in macular blood flow, and a decrease in blood velocity of optic nerve. research devices, such as laser speckle tissue circulation analyzer and blue field simulation technique, were used in previous studies. with an advancement of technology such as optical coherence tomography (oct), choroidal thickness can be measured, which indicates blood supply to outer retina. in addition, superficial retinal vasculature can be measured using optical coherence tomography angiography (octa). previous studies found that subfoveal choroidal thickness declined with increase in myopia. a negative association between subfoveal choroidal thickness and axial length was also found. a recent study found a negative association between retinal vessel density with axial length in chinese myopes using octa. therefore, caffeine consumption may further make high myopes prone to ocular diseases development due to poor ocular circulation. the current study will use octa to measure the superficial retinal vasculature and oct to measure choroidal thickness and choroidal volume of high myopes after consumption of caffeine capsule. statistical analysis normality of data will be assessed. the effect of caffeine on choroidal thickness, choroidal volume, vessel density, and perfusion density of superficial retinal layers will be analysed using repeated-measures anova (co-variates) to compare baseline data and that after caffeine consumption at various time points. if significant difference is obtained, post hoc tests will be conducted to compare results from various time points with the baseline data. difference between different age groups will be compared using unpaired t-test or mann whitney test, as appropriate.

Eligibility criteria:
inclusion criteria: * refractive error should be at least -6 diopters or lower (spherical equivalent) * best corrected visual acuity of at least 6/6 * non-smoker exclusion criteria: - diagnosed with any ocular diseases and systemic diseases

Keywords: high myopia caffeine choroidal thickness choroidal volume optical coherence tomography optical coherence tomography angiography
gemcitabine and isis 2503 in treating patients with advanced or metastatic cancer of the pancreas

Conditions: Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining gemcitabine with isis 2503 in treating patients who have advanced or metastatic cancer of the pancreas.

objectives: i. determine the 6-month and overall survival rates in patients with locally advanced or metastatic adenocarcinoma of the pancreas treated with gemcitabine and isis 2503. ii. determine the response rate of these patients treated with this regimen. iii. assess the toxicity of this regimen in this patient population. outline: this is a multicenter study. patients receive gemcitabine iv over 30 minutes on days 1 and 8 and isis 2503 iv continuously on days 1-14. treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 1 year and then every 6 months for 4 years.

Eligibility criteria:
disease characteristics: histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas not amenable to standard curative therapy duct cell undifferentiated the following cellular types are not eligible: islet cell carcinoma acinar cell carcinoma cystadenocarcinoma no cns metastases patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 no underlying disease associated with active bleeding hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) alkaline phosphatase no greater than 3 times uln ast no greater than 3 times uln pt and ptt normal renal: creatinine no greater than 1.5 times uln other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception during and for 6 months after study prior concurrent therapy: biologic therapy: at least 4 weeks since prior biologic therapy or immunotherapy no concurrent immunotherapy no colony-stimulating factors during first course of therapy chemotherapy: no prior chemotherapy except radiosensitizing agents used in adjuvant setting or in treatment of locally advanced disease no prior gemcitabine no prior isis 2503 no other concurrent chemotherapy endocrine therapy: not specified radiotherapy: no prior radiotherapy to 25% or greater of bone marrow no concurrent radiotherapy surgery: not specified

Keywords: stage iii pancreatic cancer recurrent pancreatic cancer duct cell adenocarcinoma of the pancreas adenocarcinoma of the pancreas stage iv pancreatic cancer
the effect of reiki and eft on symptom burden, disease adaptation, vital signs and catheter-related pain in hd patients

Conditions: Hemodialysis Patient

Summary: objective: this study was conducted to evaluate the effect of reiki and emotional release technique (eft) on symptom burden, disease adaptation, vital signs and catheter-related pain in haemodialysis patients. method: the study was conducted as a pretest-posttest randomised controlled experimental research model. the study was conducted in two haemodialysis units in bingöl province between september 2023 and december 2024. the population of the study consisted of all patients receiving treatment in haemodialysis units, and the sample consisted of 96 patients (reiki group =32, eft group =32 and control group =32 people) determined by power analysis. "dialysis symptom index", " tee end-stage renal failure adjustment scale", "vital signs follow-up form" and "visual analogue scale" were used for data collection.

during the research process, 8 sessions of reiki and eft were applied to the patients in the experimental groups, while the patients in the control group continued to receive routine care practices.

Eligibility criteria:
inclusion criteria: * to be over 18 years old, * to agree to participate in the research, * to be literate, * to be able to communicate verbally, * receiving three sessions of outpatient haemodialysis (hd) treatment per week in the same institution, * active use of the fistula, * no impairment in mental and cognitive functions, * receiving hd therapy for at least three months (to be considered a chronic hd programme) exclusion criteria: * refusal to participate in research, * receiving peritoneal dialysis, * to have a central venous catheter, * a psychiatric disorder diagnosed by a psychiatrist, * to withdraw from the investigation, * losing your life in the process of work, * change of institution or city,

Keywords: reiki eft hemodialysis pain symptom
neuronostatin - a glucagonotropic agent in humans?

Conditions: Type 1 Diabetes; Hypoglycemia; Type1diabetes

Summary: with the present study the investigators wish to delineate the effects of neuronostatin-13 (nst) on glucose-dependent glucagon secretion in humans. the main question it aims to answer is: • what are the physiological effects of the naturally occuring hormone nst - especially with regards to glucagonotropic effects at different plasma glucose concentrations in a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or nst.

with the present study the investigators wish to delineate the effects of neuronostatin on glucose-dependent glucagon secretion in humans. thus, this study is designed to elucidate the physiological effects of the natural occurring hormone, neuronostatin, and not to examine a medical effect of a drug or treatment. however, if neuronostatin acts glucagonotropically during low plasma glucose concentrations it could potentially help to address the unmet medical need for a treatment that, ultimately, can counteract the high risk of hypoglycaemia in patients treated with insulin. after being informed about the study and the potential risks, each participant giving written informed consent will participate in six double-blinded experimental days (day a-f) in a randomized order. on each day, participants will receive an infusion of either saline (placebo)(day a, c and e) or nst (day b, d and f). on day a and b, blood glucose will be kept at fasting levels, on day c and d blood glucose will be increased to \~8mmol/l and on day e and f blood glucose will be lowered to \~2.5mmol/l. blood glucose will be adjusted with insulin and/or glucose to reach the desired levels on each day. at the end of the study day, participants will receive an ad libitum meal. the effects of each infusion will be evaluated with regards to glucagonotropic potency, as well as a series of exploratory outcomes.

Eligibility criteria:
inclusion criteria: * normal haemoglobin \>8.3 mmol/l * normal fasting plasma glucose below 7 mmol/l * normal hba1c \<42 mmol/mol (6%) * body mass index (bmi) 18.5-27 kg/m2 * oral and written informed consent exclusion criteria: * diabetes * treatment with drugs that might interfere with glucose metabolism within a month prior to the research study * treatment with any medication that cannot be paused for 12 hours * known liver disease and/or alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) \>2 × normal values * nephropathy (egfr \<60 ml/min and/or albuminuria) * any condition that the investigator feels would interfere with trial participation

Keywords: gut hormones alpha cell pancreas incretins
efficacy and safety of celecoxib versus ibuprofen in the treatment of osteoarthritis of the knee (united states)

Conditions: Osteoarthritis, Knee

Summary: to compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (oa) of the knee.


Eligibility criteria:
inclusion criteria: * aged \>= 40 years old * diagnosed with oa of the knee according to the american college of rheumatology and oa in flare state at baseline visit * functional capacity class of i-iii exclusion criteria: * inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded) * acute joint trauma at index joint within the past 3 months with active symptoms * score of \>=20 on phq-9 or score of \>=1 on phq-9 item i * use of mobility assisting device for \<6 weeks or use of walker